Welcome Guest
Home » Reports » 3D Bioprinting Market, 2014 - 2030

3D Bioprinting Market, 2014 - 2030

Published: Mar 05, 2014
Pages: 140
Product Code: RA10011
License Type :  (Learn More)

The 3D printing industry has come a long way over the last many years; the technology has the potential of revolutionising the way things occur currently. Many industries have already benefitted from multiple advancements in this field, resulting in improved and more efficient processes worldwide. A quick look at www.3dprintingchannel.com suggests that 3D printing has multi-faceted dimensions; the technology has recently been used in varied industries such as automotive, medical, business, industrial equipments, education, architecture, and consumer products. There is a widespread optimism that it is likely to gain prominence in the coming years and have a far reaching impact on our daily lives.

 

Within healthcare, 3D printed prosthetics and implants have already been in the market for some years. Layerwise from Belgium and Xilloc from Netherlands are the major companies dealing with 3D printed medical and dental implants. Xilloc was in the news recently for creating the first customized 3D-printed lower jaw for an 83-year old patient with a serious jaw infection. Another company, Oxford Performance Materials, from USA, received FDA approval for a 3D printed implant that replaced 75% of a man’s skull.

 

Specifically, 3D bioprinting is gradually emerging as an area which is garnering attention from a lot of academicians. Some of these researchers have also recently opened start-up firms with the aim of commercialising the technology over the next decade or so.

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The ‘3D Bioprinting, 2014 - 2030’ report provides an extensive study of the emerging market of 3D bioprinting, specifically focusing on commercial bioprinters and those under development, their applications and the likely future evolution. It is widely anticipated that the 3D bioprinting market has tremendous potential: it requires hardware (bioprinters), software (CAD), biocompatible materials (bio-ink and bio-paper), each of which has the capability to grow into separate niche industries. The report covers various aspects such as technological progress, product pipeline, industry and academic research programs and regulatory concerns to assess new evolving opportunities.

 

One of the key objectives of this report is to understand the current and future state of the bioprinters and products derived thereof. This is done by analysing the following:

  • Commercial 3D Bioprinters currently available in the market
  • Innovations of academic groups across various research institutes across the globe
  • Competing technologies with similar applications in the healthcare industry
  • Size of target consumer segments
  • The widening supply-demand gap, specifically for organ transplants.

 

The base year for the report is 2014. The report provides short-mid term and long term market forecasts for the period 2014 - 2024 and 2024 - 2030, respectively. We have discussed, in detail, key drivers behind the likely growth of 3D bioprinting market. The research, analysis and insights presented in this report include the sales potential of various 3D bioprinted products based on the current expected market launch timelines, their adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.

 

 

Example Highlights

 

  1. As of today, the industry is primarily focused on research and development; apart from the limited number of industry initiatives, academic groups worldwide are involved in exemplary research in the field of 3D bioprinting.
  2. A number of start-ups have recently sprung up to develop products based on bioprinting; some of these are spin outs from university research. Examples include TeViDo BioDevices (focused on printing breast tissue), Aspect Biosystems (focused on printing tissue models for toxicity testing) and SkinPrint (focused on developing human skin).
  3. The market currently has 14 industry sponsored bioprinters, focused on a variety of commercial applications. The widening supply-demand gap for organ transplants is a huge unmet need; the eventual goal of researchers is to be able to produce bioprinted organs for organ transplants.
  4. As the development progresses, the next generation of bioprinters are likely to offer additional features (e.g. multiple arms) and are likely to be relatively more affordable driving wider adoption.
  5. We believe that the market will progress gradually over the coming decade; however, the focus is likely to shift from research to commercialisation by the second half of next decade. At this stage, applications such as drug testing and tissue engineering (skin and cartilage) are likely to be popular.
  6. By 2030, we predict 3D bioprinting to be a multi-billion dollar industry; early success of bioprinted organ transplants is likely to provide additional boost in subsequent years.

 

 

Research Methodology

 

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include

  1. Annual reports
  2. Investor presentations
  3. SEC filings
  4. Industry databases
  5. News releases from company websites
  6. Government policy documents
  7. Other analysts’ opinion reports

 

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

 

Chapter Outlines

 

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the 3D bioprinting market is headed in the mid-long term.

 

Chapter 3 provides a general introduction to 3D bioprinting. We have discussed, in detail, the origins of 3D printing and recent developments which have shaped the industry so far. The chapter also elaborates on the ‘bioprinting’ process, current and future applications, and the challenges which have to be overcome before wider adoption of the technology.

 

Chapter 4 provides an overview of the 3D bioprinting market with respect to the available bioprinting technologies and companies active in the field. The analysis also extends to regional evolution and the key drivers which will determine the future growth.

 

Chapter 5 offers a comprehensive review of the major bioprinters which have been made available by leading companies in the market. We present profiles of eight technologies with information about their origin, printing process, applications, principal features, current status and expected future evolution.

 

Chapter 6 reviews, in detail, the major bioprinters offered by academic institutions dominant in the field. We present profiles of five leading technologies with information about their origin, printing process, applications, principal features, current status and likely future evolution.

 

Chapter 7 analyses the current and future state of the worldwide market of 3D bioprinting. The chapter includes our estimates of the value of the market for end-user applications till 2030. Given the current niche nature of the technology, we have done a multi-variate sensitivity analysis to present three different tracks of industry’s evolution.

 

Chapter 8 provides our analysis of the strengths, weaknesses, opportunities and threats in the 3D bioprinting market, capturing the key elements likely to influence future growth.  

 

Chapter 9 provides case studies on Organovo and regenHU, two companies active in the 3D bioprinting arena. The case studies include detailed analysis of financial performance (where available), marketed / pipeline bioprinting products, recent developments, and future focus areas.

 

Chapter 10 is a collection of six transcripts based on our discussion with some of the leading players in the industry. The companies / academic institutes interviewed include n3D Biosciences, regenHU, Sciperio / nScrypt, MicroFab Technologies, Digilab and TeVido BioDevices.

 

Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

 

Chapters 12 and 13 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

 

 
1. PRELUDE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. 3D Printing Technology
3.2.1. What is 3D Printing?
3.2.2. Historical Evolution
3.3. 3D Bioprinting Process And Components
3.4. Entry of 3D Printing into Medical Arena
3.4.1. Key Players
3.4.2. 3D Bioprinting Applications
3.4.2.1. Toxicity Screening / Drug Testing
3.4.2.2. Tissue Engineering
3.4.2.3. Organ Replacement via Organ Printing
3.4.3. Challenges
3.4.3.1. High Initial Cost
3.4.3.2. Regulatory Issues
3.4.3.3. Functional Aspects Not Yet Fully Tested
3.4.3.4. Limited Capability for Complicated Tissues and Organs
3.4.3.5. Hurts Moral and Religious Beliefs
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Limited Professional Bioprinters in Market
4.3. Prices are Largely Prohibitive
4.4. The US is Leading the Efforts; Developing Countries Have Begun to Contribute
4.5. Start-ups Emerging as Key Players
4.6. Bioprinting: Finding its Root in University Research
4.7. Development of Multi-Arm Bioprinters: The Next Generation of Bioprinters
 
5. PROFILES: COMMERCIAL BIOPRTINERS AND PRODUCTS
5.1. Chapter Overview
 
5.2. Novogen MMX - Organovo
5.2.1. Overview and Origin
5.2.2. Development of NovoGen MMX
5.2.3. Patents
5.2.4. Awards and Accomplishments
5.2.5. The Bioprinting Process
5.2.6. Bio-ink
5.2.7. Key Features
5.2.8. Applications
5.2.8.1. Microtissues for Drug Discovery and Research
5.2.8.2. Longer Term, Organ Printing for Transplantation
5.2.8.3. Regenerative Medicine
5.2.9. Partnerships and Agreements
5.2.9.1. Pfizer
5.2.9.2. United Therapeutics
5.2.9.3. Autodesk
5.2.9.4. ZenBio
5.2.9.5. OHSU
5.2.9.6. Roche
5.2.9.7. Methuselah Foundation
5.2.9.8. NIH
 
5.3. 3D-Bioplotter - EnvisionTEC
5.3.1. Overview and Origin
5.3.2. The Bioprinting Process
5.3.3. Applications
5.3.3.1. Provides ‘smart’ scaffolds for tissue engineering
5.3.3.2. Cell and Tissue Printing
5.3.3.3. 3D-Anatomical Models for Study
5.3.4. Key Features
5.3.5. Academic Institutions using 3D Bioplotter
 
5.4. BioFactory - regenHU
5.4.1. Overview and Origin
5.4.2. Features
5.4.3. Research Collaborations
5.4.3.1. ETH, Zurich
5.4.3.2. ZHAW
5.4.4. Applications
 
5.5. BioAssembly Tool - Sciperio / nScrypt
5.5.1. Overview and Origin
5.5.2. The Bioprinting Process
5.5.3. Key Features
5.5.3.1. SmartPump
5.5.4. Collaborations
5.5.4.1. Cardiovascular Innovation Institute
5.5.5. Awards / Accomplishments
5.5.6. Applications
5.5.6.1. Bioficial Heart
5.5.6.2. Other Tissues
 
5.6. Microfluidic-based Bioprinting Platform - Aspect Biosystems
5.6.1. Overview and Origin
5.6.2. The Bioprinting Process
5.6.3. Key Features
5.6.4. Building Tissue Constructs For Drug Discovery
5.6.5. Awards
5.6.5.1. MEMSCAP Design Award 2013
5.6.5.2. Federal Support Through IRAP
 
5.7. Modified Ink-jet Bioprinter - TeVido BioDevices
5.7.1. Overview and Origin
5.7.2. Awards/Accomplishments
5.7.3. The Bioprinting Process
5.7.4. Key Features
5.7.5. Applications
5.7.5.1. Breast Reconstruction
5.7.5.2. Drug Testing
5.7.5.3. Other Reconstructive Tissue Products
5.7.5.4. Treatment for Chronic Wounds
5.7.5.5. Breast Augmentation
 
5.8. Other Initiatives
5.8.1. SkinPrint
5.8.2. 3DDiscovery - regenHU
5.8.2.1. Key Features
5.8.2.2. Research Collaborations
 
6. PRODUCT PROFILES: ACADEMIC INSTITUTES
6.1. Chapter Overview
 
6.2. BioPen - University of Wollongong / St. Vincent Hospital
6.2.1. Overview and Origin
6.2.2. The Bioprinting Process
6.2.3. Advantages of BioPen
6.2.4. Applications
 
6.3. Modified Ink-jet Bioprinter for Skin Cells - Wake Forest Institute for Regenerative Medicine / Armed Forces Institute For Regenerative Medicine
6.3.1. Overview
6.3.2. The Bioprinting Process
6.3.3. Key Features
6.3.4. Bioprinting Human Skin
6.3.5. Awards / Accomplishments
 
6.4. Modified Ink-jet Printer for Tissues and Organs - Wake Forest Institute for Regenerative Medicine
6.4.1. Overview
6.4.2. The Bioprinting Process
6.4.3. Applications
6.4.3.1. Tissue Patches
6.4.3.2. Potential to Print Organs
6.4.3.3. Organs on a Chip
6.4.4. Awards/Accomplishments
 
6.5. Regenovo - Hangzhou Dianzi University, China
6.5.1. Overview
6.5.2. The Bioprinting Process
6.5.3. Key Features
6.5.4. Limitations
6.5.5. Applications
 
6.6. Valve Based Technology - Heriot-Watt University / Roslin Cellab
6.6.1. Overview and Origin
6.6.2. The Bioprinting Process
6.6.3. Key Features
6.6.4. Applications
6.6.4.1. Drug Testing for Pharmaceutical Research
6.6.4.2. Tissue Regeneration
6.6.4.3. Custom-built Replacement Organs
6.6.5. Awards / Accomplishments
6.6.6. Collaborations
6.6.6.1. Reinnervate Ltd.
 
7. MARKET FORECAST
7.1. Chapter Overview
7.2. Forecast Methodology
7.3. The 3D Bioprinting Market, 2014 - 2030
7.3.1. Background
7.3.2. Market Forecast: Drug Testing (Base Scenario)
7.3.3. Market Forecast: 3D Bioprinted Skin (Base Scenario)
7.3.4. Market Forecast: 3D Printed Cartilage Replacement (Base Scenario)
7.3.5. Market Forecast: 3D Printed Organ Transplants (Base Scenario)
7.3.6. Overall Market Forecast (Base Scenario)
 
8. SWOT ANALYSIS
8.1. Chapter Overview
8.2. Strengths
8.2.1. Faster Drug Discovery
8.2.2. A Quality Alternative to Animal Testing
8.3. Weaknesses
8.3.1. High Initial Investment
8.3.2. Integration of Vascular Network
8.4. Opportunities
8.4.1. Low Entry Barriers
8.4.2. Growing Wait List for Organ Transplants – A Huge Unmet Need
8.5. Threats
8.5.1. Regulatory Barrier
8.5.2. Commercial 3D Cell Culture Systems
 
9. CASE STUDIES
9.1. Organovo Holdings, Inc.
9.2. regenHU
 
10. INTERVIEW TRANSCRIPTS
10.1. Interview 1: n3D Biosciences (Glauco R. Souza, President and CSO & Hubert Tseng, Senior Research Scientist)
10.2. Interview 2: regenHU (Marc Thurner, CEO)
10.3. Interview 3: Sciperio  / nScrypt (Kenneth Church, President and CEO & Xudong Chen, Vice President)
10.4. Interview 4: MicroFab Technologies (Anonymous)
10.5. Interview 5: Digilab (Dr. Igor Zlatkin, Application Scientist & Chirantan Kanani, Technology and Product Development)
10.6. Interview 6: TeVido BioDevices (Laura Bosworth, CEO and Co-Founder)
 
11. CONCLUSION
11.1. 3D Bioprinting has Emerged Well Since Inception
11.2. Commercial Bioprinters Are Limited; Research Labs and Spin-outs from Academia Continue to Progress
11.3. Organ Supply - Demand Gap: A Major Growth Driver
11.4. Overall a Multi-billion Dollar Opportunity by 2030
11.5. Challenges Exist Before Bioprinting Becomes Mainstream
 
12. APPENDIX 1: LIST OF COMPANIES AND ORGANISATIONS
 
13. APPENDIX 2: TABLES
 

 

Figure 3.1 The ‘Bioprinting’ Process

 

Figure 4.1 Industry Sponsored Bioprinters: Regional Distribution

 

Figure 4.2 Industry Sponsored Bioprinters: Distribution by Status

 

Figure 4.3 University Sponsored Bioprinters: Regional Distribution

 

Figure 5.1 Bioplotter: Printing Process

 

Figure 7.1 Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)

 

Figure 7.2 Drug Testing Market, Long Term, Base Scenario (USD MM)

 

Figure 7.3 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)

 

Figure 7.4 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)

 

Figure 7.5 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)

 

Figure 7.6 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)

 

Figure 7.7 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)

 

Figure 7.8 Overall 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)

 

Figure 7.9 Overall 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)

 

Figure 10.1 Process of Magnetic Bioprinting

 

Figure 10.2 3D Cell Bioprinting: Magnetically Beyond Rings and Dots

 

Figure 10.3 n3D vs. Organovo 3D Bioprinting

 

Figure 11.1 3D Bioprinting Market, 2018, 2024, 2030 (USD MM)

 

Figure 11.2 3D Bioprinting: The Driving Forces

 

 

Table 3.1 RepRap Project: 3D Printing Machines

 

Table 3.2 Inputs for 3D Bioprinting

 

Table 4.1 List of Bioprinters: Industry Sponsored

 

Table 4.2 Companies Developing Bioprinted Products for Commercial Purposes

 

Table 4.3 Universities Working in the Area of Bioprinting

 

Table 5.1 NovoGen MMX: Patent Portfolio

 

Table 5.2 Materials Used for Scaffolds

 

Table 5.3 SmartPump - Models and Features

 

Table 7.1: 3D Bioprinted Applications: Launch Timeline

 

Table 7.2 3D Bioprinted Skin: Competitive Landscape

 

Table 8.1 SWOT Analysis

 

Table 8.2 3D Cell Culture Systems

 

Table 9.1 3D Liver Assays - Launch Timeline

 

Table 9.2 Organovo’s Plans for Revenue Generation from 3D Bioprinted Liver

 

Table 9.3 Organovo Revenues – 2011, 2012, and Q1 2013

 

Table 9.4 regenHU: 3D Bioprinting Product Portfolio

 

Table 13.1 Industry Sponsored Bioprinters: Regional Distribution

 

Table 13.2 Industry Sponsored Bioprinters: Distribution by Status

 

Table 13.3 University Sponsored Bioprinters: Regional Distribution

 

Table 13.4 Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)

 

Table 13.5 Drug Testing Market, Long Term, Base Scenario (USD MM)

 

Table 13.6 Drug Testing Market, Short-Mid Term, Conservative Scenario (USD MM)

 

Table 13.7 Drug Testing Market, Long Term, Conservative Scenario (USD MM)

 

Table 13.8 Drug Testing Market, Short-Mid Term, Optimistic Scenario (USD MM)

 

Table 13.9 Drug Testing Market, Long Term, Optimistic Scenario (USD MM)

 

Table 13.10 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)

 

Table 13.11 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)

 

Table 13.12 3D Bioprinted Skin Market, Short-Mid Term, Conservative Scenario (USD MM)

 

Table 13.13 3D Bioprinted Skin Market, Long Term, Conservative Scenario (USD MM)

 

Table 13.14 3D Bioprinted Skin Market, Short-Mid Term, Optimistic Scenario (USD MM)

 

Table 13.15 3D Bioprinted Skin Market, Long Term, Optimistic Scenario (USD MM)

 

Table 13.16 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)

 

Table 13.17 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)

 

Table 13.18 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Conservative Scenario (USD MM)

 

Table 13.19 3D Bioprinted Cartilage Replacement Market, Long Term, Conservative Scenario (USD MM)

 

Table 13.20 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Optimistic Scenario (USD MM)

 

Table 13.21 3D Bioprinted Cartilage Replacement Market, Long Term, Optimistic Scenario (USD MM)

 

Table 13.22 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)

 

Table 13.23 3D Bioprinted Organ Transplants, Long Term, Conservative Scenario (USD MM)

 

Table 13.24 3D Bioprinted Organ Transplants, Long Term, Optimistic Scenario (USD MM)

 

Table 13.25 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)

 

Table 13.26 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)

 

Table 13.27 3D Bioprinted Products Market, Short-Mid Term, Conservative Scenario (USD MM)

 

Table 13.28 3D Bioprinted Products Market, Long Term, Conservative Scenario (USD MM)

 

Table 13.29 3D Bioprinted Products Market, Short-Mid Term, Optimistic Scenario (USD MM)

 

Table 13.30 3D Bioprinted Products Market, Long Term, Optimistic Scenario (USD MM)

 

 

The following companies have been mentioned in the report.

 

  1. 3D Biotek
  2. 3D Systems
  3. Advanced Biomatrix
  4. Amgen
  5. Aspect Biosystems
  6. Asyril
  7. Autodesk
  8. Avita Medical
  9. BD Biosciences
  10. Bespoke Innovations
  11. Bio3D Technologies
  12. CellASIC
  13. CMC Microsystems
  14. Cornell
  15. CP Automation
  16. Cuspis LLC
  17. Cyfuse Biomedical
  18. Cyprotex
  19. Digilab
  20. DTM
  21. EnvisionTEC
  22. GlycosanBiosystems
  23. Hangzhou Dianzi University, China
  24. Helisys Inc.
  25. Heriot-Watt University
  26. i.materialise
  27. ImmunoGen
  28. InSphero AG
  29. Invetech
  30. Invetechon
  31. Invitrogen
  32. Kor Ecologic
  33. Layerwise
  34. MakerBot Industries
  35. Mayoclinic
  36. Methuselah Foundation
  37. MicroFab Technologies
  38. Modern Meadows
  39. n3D Biosciences
  40. Nano3D Biosciences
  41. National Institute of Health
  42. Neatco
  43. NovoGen
  44. Objective 3D
  45. Objet Geometries Ltd
  46. Organovo Holdings, Inc.
  47. Oregon Health & Science University
  48. Oxford Performance Materials
  49. Pfizer
  50. QGel
  51. Rainbow Biosciences
  52. regenHU
  53. Reinnervate
  54. Roche
  55. Roland DG Corporation
  56. Roslin Cellab
  57. Sanofi
  58. Sciperio / nScrypt
  59. Scivax
  60. Seattle Genetics
  61. SkinPrint
  62. Solidscape
  63. Stratasys
  64. Tengion
  65. TeVido BioDevices
  66. The Technology Partnership
  67. Unique Technology
  68. United Therapeutics
  69. Vidi
  70. Vivos Dental
  71. Wake Forest Institute for Regenerative Medicine
  72. Widex
  73. Xilloc
  74. Xillocto
  75. Z Corporation
  76. ZenBio
  77. Zurich University of Applied Sciences
  78. Zyoxel

 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security